Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

CeNeS, With Phase III Data Under Belt, Raises £11.4M

Oct. 6, 2004

UK Consolidation: Etiologics, Argenta Plan For £12M Merger

Oct. 6, 2004

UK Consolidation: Etiologics, Argenta Plan For £12M Merger

Oct. 6, 2004

CeNeS, With Phase III Data Under Belt, Raises £11.4M

Oct. 6, 2004

VASTox Seeking £15M On AIM For Chemical Genomics

Oct. 6, 2004

UK Consolidation: Etiologics, Argenta Plan For £12M Merger

Oct. 5, 2004

UK Consolidation: Etiologics, Argenta Plan For £12M Merger

Oct. 5, 2004

Physiomics Enters Deal With Bayer, Eyes IPO On AIM Index

Sep. 29, 2004

Physiomics Enters Deal With Bayer, Eyes IPO On AIM Index

Sep. 29, 2004

CeNeS Reports Positive Phase III M6G Data In Post-Operative Pain

Sep. 22, 2004

View All Articles by Nuala Moran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...